Li Xun, Shen Lin, Tan Hongzhuan
Department of Epidemiology and Health Statistics, School of Public Health, Central South University, Changsha, Hunan, China.
PLoS One. 2014 May 13;9(5):e97230. doi: 10.1371/journal.pone.0097230. eCollection 2014.
Transforming growth factor-beta 1 (TGF-β1) is thought to be involved in the pathogenesis of preeclampsia (PE), but the results are inconsistent among studies. This article aims to compile an overview of the studies about the associations of TGF-β 1 polymorphism and plasma level with PE risk and to provide recommendations for future research.
The databases PubMed, Embase and Web of Science were searched up to December 2013. Five studies investigating the associations of four polymorphisms with the risks of PE were involved. A meta-analysis was conducted for the 869T>C polymorphism and PE risk. The results show that genotype TT of 869T>C polymorphism is a protective factor of PE (pooled odds ratio=0.73, 95% CI: 0.56, 0.95). Eight case-control studies reported the plasma level of TGF-β 1. The substantial heterogeneity among studies may be attributed to the differences in the blood sample processing and the TGF-β 1 analysis kits. The results suggest that plasma TGF-β 1 level in the second trimester was significantly lower in the PE group than in the normal pregnancy group, but was significantly higher in the PE group during the third trimester.
The current results support that the TGF-β 1 869 T>C polymorphism was associated with the risk of PE. However, the number of eligible studies is small and more studies are needed to clarify whether this association can be detected on larger sample sizes and different populations. Owing to the heterogeneity between studies, no conclusion on the association between plasma TGF-β 1 level and PE risk can be drawn from this review. Further studies about the TGF-β 1 levels at different stages of pregnancy and the development of TGF-β 1 assay methodology are required to reveal the role of TGF-β 1 in the pathological development of PE.
转化生长因子-β1（TGF-β1）被认为与子痫前期（PE）的发病机制有关，但研究结果并不一致。本文旨在汇总有关TGF-β1多态性和血浆水平与PE风险关联的研究综述，并为未来研究提供建议。
检索了截至2013年12月的PubMed、Embase和Web of Science数据库。纳入了五项研究四种多态性与PE风险关联的研究。对869T>C多态性与PE风险进行了荟萃分析。结果显示，869T>C多态性的TT基因型是PE的保护因素（合并比值比=0.73，95%可信区间：0.56，0.95）。八项病例对照研究报告了TGF-β1的血浆水平。研究之间存在显著异质性，可能归因于血样处理和TGF-β1分析试剂盒的差异。结果表明，PE组孕中期血浆TGF-β1水平显著低于正常妊娠组，但孕晚期PE组血浆TGF-β1水平显著高于正常妊娠组。
目前的结果支持TGF-β1 869T>C多态性与PE风险相关。然而，符合条件的研究数量较少，需要更多研究来阐明在更大样本量和不同人群中是否能检测到这种关联。由于研究之间存在异质性，本综述无法得出血浆TGF-β1水平与PE风险之间关联的结论。需要进一步研究妊娠不同阶段的TGF-β1水平以及TGF-β1检测方法的发展，以揭示TGF-β1在PE病理发展中的作用。
